Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• CRISPR/Cas9 for overcoming drug resistance in solid tumors

  2019cited by this paper
• CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment.

  2019cited by this paper
• Afatinib restrains K-RAS–driven lung tumorigenesis

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• Binding of Dickkopf-3 to CXCR7 Enhances Vascular Progenitor Cell Migration and Degradable Graft Regeneration

  2018cited by this paper
• Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis

  2017cited by this paper
• KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

  2017cited by this paper
• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

  2017cited by this paper
• Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

  2017cited by this paper
• Mechanisms of resistance to EGFR-targeted drugs: lung cancer

  2016cited by this paper
• Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

  2016cited by this paper
• Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

  2016cited by this paper
• EGFR and NF-κB: partners in cancer.

  2015cited by this paper
• NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

  2015cited by this paper
• MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP‐70 signaling, and lymphocyte chemotaxis

  2015cited by this paper
• NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

  2015cited by this paper
• Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activation

  2015cited by this paper
• KRAS: feeding pancreatic cancer proliferation.

  2014cited by this paper
• The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation

  2014cited by this paper
• CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression

  2014cited by this paper
• C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment

  2014cited by this paper
• CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment

  2014cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

  2014cited by this paper
• Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma*

  2014cited by this paper
• Macrophage Migration Inhibitory Factor Limits Activation-Induced Apoptosis of Platelets via CXCR7-Dependent Akt Signaling

  2014cited by this paper
• CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential

  2013cited by this paper
• Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth in Vivo

  2013cited by this paper
• CXCR7 impact on CXCL12 biology and disease.

  2013cited by this paper
• CXCR4/CXCL12 in Non-Small-Cell Lung Cancer Metastasis to the Brain

  2013cited by this paper
• CXCR7 mediated Giα independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells.

  2012cited by this paper
• Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells

  2012cited by this paper
• Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

  2012cited by this paper
• Molecular and Cellular Pathobiology The IL-8 – Regulated Chemokine Receptor CXCR 7 Stimulates EGFR Signaling to Promote Prostate Cancer Growth

  2011cited by this paper
• FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• Isolation and Functional Analysis of CXCR7 Promoter - a Novel Receptor for Stromal Derived Factor-1 (SDF-1): Different Regulation of Expression in Human Hematopoietic Cells Versus Pediatric Sarcomas.

  2009cited by this paper
• β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7

  2009cited by this paper
• KRAS mutations in non-small cell lung cancer.

  2009cited by this paper
• CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival.

  2009cited by this paper
• Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer

  2009cited by this paper
• Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein.

  2008cited by this paper
• Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer.

  2008cited by this paper
• The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer*

  2008cited by this paper
• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

  2008cited by this paper
• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

  2007cited by this paper
• CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.

  2007cited by this paper
• A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

  2006cited by this paper
• EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

  2005cited by this paper
• Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

  2005cited by this paper
• Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

  2003cited by this paper
• Cloning and expression of the human vasoactive intestinal peptide receptor.

  1991cited by this paper
• Selective amplification and cloning of four new members of the G protein-coupled receptor family.

  1989cited by this paper
• Biologics: Targets and Therapy Dovepress Clinical and Comparative Utility of Afatinib in Non-small Cell Lung Cancer

  year unknowncited by this paper

• D-dopachrome tautomerase contributes to lung epithelial repair via atypical chemokine receptor 3-dependent Akt signaling

  2021cites this paper
• A Bispecific Inhibitor of the EGFR/ADAM17 Axis Decreases Cell Proliferation and Migration of EGFR-Dependent Cancer Cells

  2020cites this paper
• Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.

  2020cites this paper